Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Chardan

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday.

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics

Avidity unveiled promising results for its DMD treatment on Friday and the top-notch biotech stock catapulted. RNA stock is highly rated.

Investors Business Daily

Chardan Sees Over 200% Upside On This Small-Cap Cancer-Focused Stock

Chardan Sees Over 200% Upside On This Small-Cap Cancer-Focused Stock

Chardan has initiated coverage on Oncorus Inc (NASDAQ:ONCR) with a Buy rating and a price target of $5. The analysts based it on the company's commercial potential with its lead oncolytic virus immunotherapy ONCR-177 from its HSV platform. Oncorus' HSV platform utilizes the herpes simplex virus (HSV) type 1 backbone that incorporates more transgenes,…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive

CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies.

Analysts Cuts Price Target On This Small Cap But Remain Bullish

Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ:VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse large B-cell lymphoma and chronic lymphocytic leukemia. It also…

Valens' Collaboration With Logitech Gets Thumbs Up From This Analyst

Chardan analyst Brian Dobson is optimistic about Valens Semiconductor Ltd's (NYSE:VLN) collaboration with Logitech International SA (NASDAQ:LOGI). He acknowledges that the collaboration provides an implicit stamp of approval which should aid Valens in winning future business in the audio-video segment, representing 80% of revenue forecast for 2022E. VLN is joining forces with Logitech, an industry-leading electronics…

Organisations

Sarepta Therapeutics

Alnylam Pharmaceuticals

Logitech International SA

Avidity Biosciences

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

296,139 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play